

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
IPC display formats
NEWS 3 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 4 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 5 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 6 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 8 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats
NEWS 9 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 10 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 11 MAY 30 INPAFAMDB now available on STN for patent family
searching
NEWS 12 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
sequence search option
NEWS 13 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 14 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 15 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications
NEWS 16 JUN 19 CAS REGISTRY includes selected substances from
web-based collections
NEWS 17 JUN 25 CA/CAPLUS and USPAT databases updated with IPC
reclassification data
NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 21 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 22 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 23 JUL 28 EPFULL enhanced with additional legal status
information from the EPOLINE Register
NEWS 24 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25 JUL 28 STN Viewer performance improved
NEWS 26 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts

page images from 1967-1998
 NEWS 28 AUG 15 CAOLD to be discontinued on December 31, 2008
 NEWS 29 AUG 15 CAplus currency for Korean patents enhanced
 NEWS 30 AUG 25 CA/Caplus, CASREACT, and IFI and USPAT databases
 enhanced for more flexible patent number searching
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:36:59 ON 27 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:37:29 ON 27 AUG 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 AUG 2008 HIGHEST RN 1043895-06-2
 DICTIONARY FILE UPDATES: 26 AUG 2008 HIGHEST RN 1043895-06-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searches in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10551502.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 13:38:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 14737 TO ITERATE

13.6% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 287468 TO 302012

PROJECTED ANSWERS: 22225 TO 26407

L2 50 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10551502\Struc 2.str



```

chain nodes :
13 14 15 16 17 18 19 20 21 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
4-7 6-25 10-13 13-14 13-15 16-17 17-21 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
6-25 13-14 13-15 16-17 17-21 18-19 18-20
exact bonds :
4-7 10-13

```

normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:[*1],[*2]

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
 19:CLASS 20:CLASS 21:CLASS 25:CLASS 26:CLASS 27:Atom

L3 STRUCTURE UPLOADED

=> d
 L3 HAS NO ANSWERS
 L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> l3
 SAMPLE SEARCH INITIATED 13:41:26 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 532 TO ITERATE
 100.0% PROCESSED 532 ITERATIONS 13 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 9257 TO 12023
 PROJECTED ANSWERS: 44 TO 476

L4 13 SEA SSS SAM L3

=> l3 full
 FULL SEARCH INITIATED 13:41:32 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 9653 TO ITERATE
 100.0% PROCESSED 9653 ITERATIONS 264 ANSWERS
 SEARCH TIME: 00.00.01

L5 264 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	181.12	181.33

FILE 'CAPLUS' ENTERED AT 13:41:35 ON 27 AUG 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Aug 2008 VOL 149 ISS 9
FILE LAST UPDATED: 26 Aug 2008 (20080826/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> 15

L6 23 L5

=> d ibib abs hitstr 1-23

L6 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:733338 CAPLUS

DOCUMENT NUMBER: 149:79406

TITLE: Preparation of bicyclic acyltryptophanols as effective FSH antagonists

INVENTOR(S): Wortmann, Lars; Menzenbach, Bernd; Kopitz, Marcus; Kosemund, Dirk; Muhn, Hans-Peter; Schrey, Anna; Kuehne, Ronald; Frenzel, Thomas; Liesener, Florian Peter

PATENT ASSIGNEE(S): Bayer Schering Pharma Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 217pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008071455	A1	20080619	WO 2007-EP11222	20071215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,			

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 EP 1956016 A1 20080813 EP 2006-77263 20061215
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, RS
 PRIORITY APPLN. INFO.: EP 2006-77263 A 20061215
 US 2006-874962P P 20061215
 OTHER SOURCE(S): MARPAT 149:79406
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to acyltryptophanols I [Q = monocyclic aryl or heteroaryl; V = cycloalkylene, cycloalkenylene, heterocycloalkylene, heterocycloalkenylene; X = bond, C1-4-alkylene, C2-6-alkenylene, C2-4-alkynylene; W = aryl, heteroaryl; R1 = H, (un)substituted C1-6-alkyl, C3-6-alkenyl, C3-6-alkynyl, C3-7-cycloalkyl, C1-6-alkoxy-(C1-6-alkylene), C3-7-cycloalkoxy-(C1-6-alkylene), etc.; R2 = H, halogen, CN, SO2Me, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, OCH2Ph (with the hydrocarbons optionally fluorinated one or more times); R3 = H, OH, halogen, NO2, NH2, CN, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, hydroxy-C1-6-alkylene, hydroxy-C2-6-alkenylene, hydroxy-C1-6-alkynylene, C1-6-alkoxy, etc; R4, R5, R6, = H, OH, halogen, NO2, NH2, CN, Ph, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-(C1-6-alkylene), C3-7heterocycloalkyl (wherein the hydrocarbons may be substituted by F, CN, pyrrolidino, morpholino, thiamorpholino, etc.); R7, R8 = H, Me, Et (whereby Me and Et are optionally fluorinated one or more times)]. One process comprises coupling of tryptophanol derivative II with carboxylic acids III via: (a) conversion of said carboxylic acid into an intermediate active ester or carbonyl chloride with a suitable peptide-coupling reagent, or SOCl2, ClC(O)C(O)Cl, phosgene or a derivative thereof, where appropriate in the presence of a base; and (b) reacting the active intermediate with tryptophanol. Thus, 6-[3-chloro-4-(methylcarbamoyl)phenyl]-2H-chromene-8-carboxylic acid [(R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]amide (IV) was prepared from Me 6-iodo-2H-chromene-8-carboxylate via saponification with KOH in MeOH, amidation with D-tryptophanol in DMF containing EDC and HOBT, and coupling reaction with [3-chloro-4-(methylcarbamoyl)phenyl]boronic acid in EtOH containing aqueous Na2CO3 and catalytic Pd(PPh3)4. The compds. according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis. The physiol. activity of IV was determined [IC50 = 130nm FSH-antagonistic effect in HTRF assay].
 IT 1033765-82-OP
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and borohydride reduction of; preparation of bicyclic acyltryptophanols
 as effective FSH antagonists)
 RN 1033765-82-0 CAPLUS

CN Tryptophan, N-[6-[3-chloro-4-[(methylamino)carbonyl]phenyl]-2,2-dimethyl-2H-1-benzopyran-8-yl]carbonyl]-5,7-difluoro-, ethyl ester (CA INDEX NAME)



IT 1033765-83-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrogenation of; preparation of bicyclic
 acyltryptophanols as
 effective FSH antagonists)
 RN 1033765-83-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



IT 1033763-44-8P 1033763-48-2P 1033763-49-3P
 1033763-56-2P 1033763-61-9P 1033763-69-7P
 1033763-70-0P 1033763-72-2P 1033763-73-3P
 1033764-38-3P 1033764-39-4P 1033764-40-7P
 1033764-70-3P 1033765-20-6P 1033765-21-7P
 1033765-22-8P 1033765-23-9P 1033765-24-0P
 1033765-25-1P 1033765-39-7P 1033765-40-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of bicyclic acyltryptophanols as effective FSH antagonists)

RN 1033763-44-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1033763-48-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1033763-49-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033763-69-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033763-70-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1033763-72-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1033763-73-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1033764-38-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033764-39-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1033764-40-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1033764-70-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033765-20-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033765-21-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033765-22-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033765-23-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033765-24-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1033765-25-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1033765-39-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1033765-40-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 1033763-43-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation, FSH antagonistic activity and hydrogenation of; preparation of bicyclic acyltryptophanols as effective FSH antagonists)

RN 1033763-43-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:493007 CAPLUS

DOCUMENT NUMBER: 148:517400

TITLE: Biaryl compounds as serine protease inhibitors and their preparation, and use in the treatment of clotting disorders

INVENTOR(S): Babu, Yarlagadda S.; Rowland, R. Scott; Chand, Pooran; Kotian, Pravin L.; El-Kattan, Yahya; Niwas, Shri

PATENT ASSIGNEE(S): Biocryst Pharmaceuticals, Inc., USA

SOURCE: U.S., 166pp., Cont.-in-part of Appl. No.

PCT/US2001/32582.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6699994	B1	20040302	US 2002-127460	20020423
WO 2002034711	A1	20020502	WO 2001-US32582	20011022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 20040162281	A1	20040819	US 2003-738027	20031218


US 6936719
PRIORITY APPLN. INFO.:

B2 20050830

US 2001-281735P P 20010406
WO 2001-US32582 A2 20011022
US 2000-241848P P 20001020
US 2002-127460 A3 20020423

OTHER SOURCE(S): MARPAT 148:517400

GI



AB Compds. of formula I are useful as inhibitors of trypsin like serin protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compds. could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents. Compds. of formula I E1 and L are independently 5- to 7-membered (un)saturated carbocycle, (un)saturated bicyclic ring, (un)substituted (un)saturated 1-8 hydrocarbon chain; R is CH=CH-R2-, C.tplbond.C-R2, CR2=CH2., etc.; R1 and A are independently H, NO2, CN, halo, N2, C1-8 alkyl, etc.; m is 1 except E1 is a cyclic ring of more than 5 atoms, then m is 1 or higher; R2 is H, halo, (halo)alkyl, (CH2)0-4phenyl, etc.; W is a bond, CHR2, CH=CHR2, OCH2, CCR2=CR2, etc.; E2 is 5- to 7-membered (un)saturated (hetero)cyclic ring, C1-8 alkyl, C2-8 alkenyl, etc.; each X is independently a bond, (un)substituted C1-4 methylene chain, O, S, NH and derivs., etc.; B and B1 are independently H, halo, CN, NH2, (un)substituted C1-8 alkyl, etc.; o is 1 except when L is a cyclic ring of more than 5 atoms, then o is 1 and higher; V and V1 are independently R1, N-alkyl substituted carboxamidyl, etc.; p is 1 except when E2 is a cyclic ring of more than 5 atoms, then p is 1 and higher; and their pharmaceutically acceptable salts and prodrugs thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their serine protease inhibitory activity (some data given).


IT 1021429-82-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of biaryl compds. as serine protease inhibitors useful in the treatment of clotting disorders)

RN 1021429-82-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-4-[[[2-methylpropyl]amino]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:124784 CAPLUS

DOCUMENT NUMBER: 148:183378

TITLE: Assay for differentiating compounds that modulate the extrinsic and/or intrinsic coagulation pathways

INVENTOR(S): Wang, Xinkang; Hsu, Mei-Yin; Wong, Pancras C.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 13pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080026474	A1	20080131	US 2007-782660	20070725
PRIORITY APPLN. INFO.:			US 2006-833674P	P 20060727

AB Methods for differentiating compds. that modulate the extrinsic and/or intrinsic coagulation pathways are provided. Also provided are methods for identifying a compound that modulates the extrinsic coagulation pathway. In addition, methods for determining an effective dosage of an anticoagulant in a patient are provided.


IT 1004551-41-0

RL: PAC (Pharmacological activity); BIOL (Biological study)
(assay for differentiating compds. that modulate extrinsic and/or intrinsic coagulation pathways)

RN 1004551-41-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[(2S,4R)-6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinoliny]-5'-[(3-methyl-1-oxobutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:43636 CAPLUS

DOCUMENT NUMBER: 148:121398

TITLE: Cycloalkylcarboxamides and related compounds as modulators of ATP-binding cassette transporters and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Hadida Ruah, Sara S.; Miller, Mark T.; Bear, Brian; McCartney, Jason; Grootenhuis, Peter D. J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 422pp., Cont.-in-part of U.S. Ser. No. 647,092.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080009524	A1	20080110	US 2007-824606	20070629
US 20080044355	A1	20080221	US 2006-647092	20061228
PRIORITY APPLN. INFO.:			US 2005-754558P	P 20051228
			US 2006-802580P	P 20060522
			US 2006-647092	A2 20061228

OTHER SOURCE(S): MARPAT 148:121398

GI



I



II

AB Comps. of formula I and pharmaceutically acceptable compns. thereof, are useful as modulators of ATP -Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The invention also relates to methods of treating ABC transporter mediated diseases using compds. of formula I. Compds. of formula I wherein each R1 is independently (un)substituted C1-6 aliphatic, (un)substituted (hetero)aryl, (un)substituted C3-10 cycloaliph. and (un)substituted 4- to 10-membered heterocycloaliph., carboxy, amido, amino, halo and OH provided that at least one of R1 is (un)substituted (hetero)aryl attached to the 3- or 4-position of the Ph ring; R2 is H, (un)substituted C1-6 aliphatic, (un)substituted C3-6 cycloaliph., (un)substituted Ph, and (un)substituted heteroaryl; Ring A is (un)substituted cycloaliph., and (un)substituted heterocycloaliph. where the atoms of ring A adjacent to C* are carbon atoms; R4 is (un)substituted (hetero)aryl; n is 1, 2, 3, 4, and 5; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their ATP-binding cassette transporter modulatory activity (some data given).


IT 945238-88-0P 945241-55-4P 945244-57-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of cycloalkylcarboxamides and related compds. as modulators of ATP-binding cassette transporters)

RN 945238-88-0 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2,2'-dimethyl- (CA INDEX NAME)



RN 945241-55-4 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-chloro-N,2'-dimethyl- (CA INDEX NAME)



RN 945244-57-5 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2-fluoro-2'-methyl- (CA INDEX NAME)



L6 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1476060 CAPLUS
 DOCUMENT NUMBER: 148:100510

TITLE: Preparation of pyridinylcarboxamide and phenylcarboxamide derivatives as prolyl hydroxylase inhibitors and methods of use

INVENTOR(S): Kawamoto, Richard Masaru

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: U.S. Pat. Appl. Publ., 53pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070299086	A1	20071227	US 2007-821936	20070626
WO 2008002576	A2	20080103	WO 2007-US14832	20070626
WO 2008002576	A3	20080703		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA


PRIORITY APPLN. INFO.: US 2006-816522P P 20060626

OTHER SOURCE(S): MARPAT 148:100510


GI




- AB Title compds. I [R and R1 independently = H, (un)substituted H, Ph, or heteroaryl; X = N or CH; Y = H, OH, OMe, or OEt; R9 = H or Me; R2 = OR6 or NR7R8; R6 = H, alkyl, or cycloalkyl; R7 and R8 independently = H, alkyl, cycloalkyl, or taken together form a ring; L = linking 1-3 carbon unit optionally substituted with Me or Et], and their pharmaceutically acceptable salts, are prepared and disclosed as prolyl hydroxylase inhibitors. Thus, e.g., II was prepared by sulfonylation of [(3,5-dihydroxypyridine-2-carbonyl)amino]acetic acid Me ester (preparation given) with trifluoromethanesulfonic acid followed by substitution with 3-chlorophenylboronic acid. I were evaluated in EGLIN 1 assays; e.g., II demonstrated an IC50 value of 2.8 μ M. The present disclosure relates to HIF-1 α prolyl hydroxylase inhibitors, compns. which comprise the HIF-1 α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
- IT 1007378-37-1P 1007378-58-6P 1007378-62-2P
1007378-65-5P 1007378-92-8P 1007379-14-7P
1007379-17-0P 1007379-20-5P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prophetic drug candidate; preparation of pyridinylcarboxamide and phenylcarboxamide derivs. as prolyl hydroxylase inhibitors and methods of use)
- RN 1007378-37-1 CAPLUS
- CN Glycine, N-[[3'-(aminocarbonyl)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1007378-58-6 CAPLUS
CN Glycine, N-[[3'-(acetylamino)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1007378-62-2 CAPLUS
CN Glycine, N-[[3-hydroxy-3'-[(1-oxopropyl)amino][1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1007378-65-5 CAPLUS
CN Glycine, N-[[3'-[(cyclopropylcarbonyl)amino]-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1007378-92-8 CAPLUS
CN Glycine, N-[[3'-(aminocarbonyl)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 1007379-14-7 CAPLUS
 CN Glycine, N-[[3'-(acetylamino)-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-
 (CA INDEX NAME)



RN 1007379-17-0 CAPLUS
 CN Glycine, N-[[3-hydroxy-3'-[(1-oxopropyl)amino][1,1'-biphenyl]-4-yl]carbonyl]-
 (CA INDEX NAME)



RN 1007379-20-5 CAPLUS
 CN Glycine, N-[[3'-[(cyclopropylcarbonyl)amino]-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]-
 (CA INDEX NAME)



L6 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:846121 CAPLUS
 DOCUMENT NUMBER: 147:211534

TITLE: Cycloalkylcarboxamides and related compounds as modulators of ATP-binding cassette transporters and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Ruah, Sara S. Hadida; Miller, Mark T.; Bear, Brian; McCartney, Jason; Grootenhuis, Peter D. J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 249pp.
CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007087066	A2	20070802	WO 2006-US49412	20061228
WO 2007087066	A3	20071025		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006336504	A1	20070802	AU 2006-336504	20061228
PRIORITY APPLN. INFO.:			US 2005-754558P	P 20051228
			US 2006-802580P	P 20060522
			WO 2006-US49412	W 20061228
OTHER SOURCE(S):	MARPAT 147:211534			
GI				



AB Comps. of formula I and pharmaceutically acceptable compns. thereof, are useful as modulators of ATP -Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The invention also relates to methods of treating ABC transporter mediated diseases using compds. of formula I. Compds. of formula I wherein each R1 is independently (un)substituted C1-6 aliphatic, (un)substituted (hetero)aryl, (un)substituted C3-10 cycloaliph. and (un)substituted 4- to 10-membered heterocycloaliph., carboxy, amido, amino, halo and OH provided that at least one of R1 is (un)substituted (hetero)aryl attached to the 3- or 4-position of the Ph ring; R2 is H, (un)substituted C1-6 aliphatic, (un)substituted C3-6 cycloaliph., (un)substituted Ph, and (un)substituted heteroaryl; Ring A is (un)substituted cycloaliph., and (un)substituted heterocycloaliph. where the atoms of ring A adjacent to C* are carbon atoms; R4 is (un)substituted (hetero)aryl; n is 1, 2, 3, 4, and 5; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their ATP-binding cassette transporter modulatory activity (some data given).


IT 945238-88-0P 945241-55-4P 945244-57-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of cycloalkylcarboxamides and related compds. as modulators of ATP-binding cassette transporters)

RN 945238-88-0 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2,2'-dimethyl- (CA INDEX NAME)



RN 945241-55-4 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-chloro-N,2'-dimethyl- (CA INDEX NAME)



RN 945244-57-5 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 5'-[[[1-(1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-2-fluoro-2'-methyl- (CA INDEX NAME)



L6 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:327723 CAPLUS
 DOCUMENT NUMBER: 146:358864

TITLE: Preparation of heterocyclyl biphenylcarboxamides for treatment of hepatitis C virus (HCV) infection.

INVENTOR(S): Wheelhouse, Christopher James; Thomas, Alexander James Floyd; Bushnell, David John; Lumley, James; Salter, James Iain; Carter, Malcolm Clive; Mathews, Neil; Pilkington, Christopher John; Angell, Richard Martyn

PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK

SOURCE: PCT Int. Appl., 170pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007031791	A1	20070322	WO 2006-GB3469	20060918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006290442	A1	20070322	AU 2006-290442	20060918
CA 2621364	A1	20070322	CA 2006-2621364	20060918
EP 1940786	A1	20080709	EP 2006-779478	20060918
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2007138242	A1	20071206	WO 2007-GB1024	20070321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
MX 200803269	A	20080409	MX 2008-3269	20080307
KR 2008050490	A	20080605	KR 2008-708964	20080415
PRIORITY APPLN. INFO.:			GB 2005-18971	A 20050916
			GB 2006-10663	A 20060530
			GB 2006-10664	A 20060530
			WO 2006-GB3469	W 20060918
OTHER SOURCE(S):		MARPAT 146:358864		
GI				




AB Title compds. [I; R1 = alkyl, A1, L1A1, A1A11, L1A1A11, A1L1A11, A1Y1A11, A1Het1A11, L1A1Y1A11, L1A1Het1A11, L1Het1A1, L1Y1A1, L1Y1Het1A1, L1Het1Y1A1, L1Y1Het1L11, A1Y1Het1A11, A1Het1Y1A11, A1Het1L1A11, A1L1Het1A11, L1Het1L11; A, B = bond, CONR', NR'CO, NR'CO2, CO, NR'CONR'', NR'SO2, SO2, NR', NR'COCO, CO2, alkylene-NR', hydroxyalkylene-NR'; R', R' = H, alkyl; R2, R3 = alkyl, alkoxy, haloalkyl, haloalkoxy, halo; m, n = 0, 1; R4 = alkyl, A4, L4A4, A4A41, L4A4A41, A4L4A41, A4Y4A41, A4Het4A41, L4A4Y4A41, L4A4Het4A41, L4Het4A4, L4Y4A4, L4Y4Het4A4, L4Het4Y4A4, L4Y4Het4L41, A44Het4A41, A4Het4Y4A41, A4Het4L4A41, A4L4Het4A41, L4Het4L41; A1, A4, A11, A41 = Ph, 5-10 membered heteroaryl, heterocyclyl, carbocyclyl; L1, L4 = alkylene, hydroxyalkylene; Y1, Y4 = CO, SO, SO2; L11, L41 = H, alkyl; Het1, Het4 = O, S, NR'; the Ph, heteroaryl, heterocyclyl and carbocyclyl moieties in R1, R4 being optionally substituted and/or fused to Ph, 5-10 membered heteroaryl, heterocyclyl], were prepared Thus, 6-methylbiphenyl-3,4'-dicarboxylic acid 4'-[(4-isoxazol-5-ylphenyl)amide] 3-[(4-morpholin-4-ylphenyl)amide] (preparation outlined) inhibited HCV replication with IC50 <1 μM.

IT 929892-30-8 929892-31-9 929892-32-0
929892-33-1 929892-34-2 929893-13-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of heterocyclyl biphenylcarboxamides for treatment of hepatitis C virus infection)


RN 929892-30-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-(3-methoxyphenyl)-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 929892-31-9 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-1H-indazol-6-yl-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 929892-32-0 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-(3-bromophenyl)-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 929892-33-1 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-[4-(5-isoxazolyl)phenyl]-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 929892-34-2 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-[(3-chlorophenyl)methyl]-2'-methyl-N4'-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 929893-13-0 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 3'-[(cyclopropylcarbonyl)amino]-N-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]-2,4'-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:175569 CAPLUS
 DOCUMENT NUMBER: 146:251733
 TITLE: Preparation of acyltryptophanols as FSH antagonists
 INVENTOR(S): Wortmann, Lars; Cleve, Arwed; Muhn, Hans-Peter; Langer, Gernot; Schrey, Anna; Kuehne, Ronald; Menzenbach, Bernd; Koppitz, Marcus; Rosemund, Dirk
 PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 404pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007017289	A2	20070215	WO 2006-EP7949	20060808
WO 2007017289	A3	20070531		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 DE 102005038632 A1 20070215 DE 2005-102005038632 20050810
 DE 102005038632 B4 20080327
 CA 2618888 A1 20070215 CA 2006-2618888 20060808
 EP 1912970 A2 20080423 EP 2006-776768 20060808
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 US 20070060573 A1 20070315 US 2006-501228 20060809
 PRIORITY APPLN. INFO.: DE 2005-102005038632A 20050810
 US 2005-706743P P 20050810
 WO 2006-EP7949 W 20060808
 OTHER SOURCE(S): MARPAT 146:251733
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. I [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; R3 = H, OH, halo, etc.; R4-R6 = H, OH, halo, etc.; or R5 and R6 may together form heterocycloalkyl, cycloalkyl; R7, R8 = H, Me, Et (Me and Et may be fluorinated); Q, W = (hetero)aryl; X = a bond, alkylene, alkenylene, etc.; Y = a bond, alkylene] which are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis, were prepared E.g., a multi-step synthesis of II, starting from 5-bromo-DL-tryptophan, was given. II showed IC50 of 7 μ M when tested for FSH-antagonistic effect in the HTRF assay. Pharmaceutical composition comprising the compound I is disclosed.

IT 925937-80-OP 925937-83-3P 925937-85-5P
 925939-41-9P 925939-55-5P 925939-68-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of acyltryptophanols as FSH antagonists)

RN 925937-80-0 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-(1H-indol-3-ylmethyl)ethyl]-N4'-methyl-4-propoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 925937-83-3 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[2-(5-fluoro-1H-indol-3-


yl)-1-(hydroxymethyl)ethyl]-N4'-methyl-4-propoxy- (CA INDEX NAME)



RN 925937-85-5 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-(1-methyl-1H-indol-3-yl)methyl]ethyl]-N4'-methyl-4-propoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 925939-41-9 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-(1H-indol-3-yl)methyl]ethyl]-4-propoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 925939-55-5 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[2-(5-fluoro-1H-indol-3-yl)-1-(hydroxymethyl)ethyl]-4-propoxy- (CA INDEX NAME)



RN 925939-68-0 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 3'-chloro-N3-[(1R)-2-hydroxy-1-[(1-methyl-1H-indol-3-yl)methyl]ethyl]-4-propoxy- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1096119 CAPLUS
 DOCUMENT NUMBER: 145:438417
 TITLE: Substituted 3,4'-biphenyldicarboxamides as p38 kinase inhibitors, and their preparation, pharmaceutical compositions, and use
 INVENTOR(S): Boehm, Jeffrey C.; Callahan, James Francis; Wan, Zehong; Yan, Hongxing
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 130pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110173	A2	20061019	WO 2005-US35743	20051005
WO 2006110173	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1805132 A2 20070711 EP 2005-857821 20051005
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
 JP 2008515898 T 20080515 JP 2007-535764 20051005
 US 20080051416 A1 20080228 US 2007-576748 20070405
 PRIORITY APPLN. INFO.: US 2004-616065P P 20041005
 US 2005-719729P P 20050922
 WO 2005-US35743 W 20051005
 OTHER SOURCE(S): MARPAT 145:438417
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. I, and their pharmaceutically acceptable derivs., and their use as
 pharmaceuticals, particularly as p38 kinase inhibitors, are disclosed
 [wherein R1 = H, (un)substituted cyclo/alkyl, hetero/aryl, heterocyclyl;
 R2 = H, (un)substituted cyclo/alkyl; or R2N(CH2)mR1 = 4- to 6-membered
 heterocyclyl; R3 = halo, Me; R8 = H, (un)substituted cyclo/alkyl, Ph,
 heteroaryl; X, Y = independently H, Me, halo; Z = (CH2)qCOOR9,
 (CH2)qNR9R10; R9, R10 = independently H, (un)substituted alkyl,
 hetero/aryl, etc.; or R9NR10 = 5- to 6-membered ring; m, q = independently
 0-4; n = 0-2; ; or pharmaceutically acceptable salts and derivs. thereof].
 Thus, Pd-coupling of Me 2-bromo-5-[[2,2-dimethylpropyl]amino]carbonyl]ben
 zoate (preparation given) with 4-methyl-3-(4,4,5,5-tetramethyl-
 [1,3,2]dioxaborolan-2-yl)benzoic acid followed by amidation of the
 biphenylcarboxylic acid with 2-aminoethanol gave dicarboxamide II. In a
 fluorescence anisotropy kinase binding assay, II had a pIC50 value of
 <4.8.
 IT 913002-55-8P 913002-56-9P 913002-57-0P
 913002-63-8P 913002-68-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of biphenyldicarboxamides as p38 kinase
 inhibitors)
 RN 913002-55-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-[[2,2-dimethylpropyl]amino]carbonyl]-
 5'-[[2-hydroxyethyl]amino]carbonyl]-2'-methyl-, methyl ester (CA INDEX
 NAME)




RN 913002-56-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-2'-methyl-, methyl ester (CA INDEX NAME)




RN 913002-57-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-2'-methyl- (CA INDEX NAME)




RN 913002-63-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-[[(2,2-dimethylpropyl)amino]carbonyl]-5'-[[(2-hydroxyethyl)amino]carbonyl]-2'-methyl- (CA INDEX NAME)



RN 913002-68-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5'-[(cyclopropylamino)carbonyl]-4-
[[2,2-dimethylpropyl]amino]carbonyl]-3'-fluoro-2'-methyl- (CA INDEX
NAME)



IT 913001-79-3P 913001-80-6P 913001-81-7P
 913001-82-8P 913001-83-9P 913001-84-0P
 913001-85-1P 913001-86-2P 913001-87-3P
 913001-88-4P 913001-89-5P 913001-90-8P
 913001-91-9P 913001-92-0P 913001-93-1P
 913001-94-2P 913001-95-3P 913001-96-4P
 913001-97-5P 913001-98-6P 913001-99-7P
 913002-00-3P 913002-01-4P 913002-02-5P
 913002-03-6P 913002-04-7P 913002-05-8P
 913002-06-9P 913002-08-1P 913002-09-2P
 913002-10-5P 913002-11-6P 913002-12-7P
 913002-13-8P 913002-14-9P 913002-15-0P
 913002-16-1P 913002-17-2P 913002-18-3P
 913002-19-4P 913002-20-7P 913002-21-8P
 913002-22-9P 913002-23-0P 913002-24-1P
 913002-25-2P 913002-26-3P 913002-27-4P
 913002-28-5P 913002-29-6P 913002-30-9P
 913002-31-0P 913002-32-1P 913002-33-2P
 913002-34-3P 913002-35-4P 913002-36-5P
 913002-37-6P 913002-38-7P 913002-39-8P
 913002-40-1P 913002-41-2P 913002-42-3P
 913002-43-4P 913002-44-5P 913002-45-6P
 913002-46-7P 913002-47-8P 913002-48-9P
 913002-49-0P 913002-50-3P 913002-51-4P
 913002-52-5P 913002-53-6P 913002-54-7P
 913002-58-1P 913002-59-2P 913002-60-5P
 913002-61-6P 913002-62-7P 913002-64-9P
 913002-65-0P 913002-66-1P 913002-67-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biphenyldicarboxamides as p38 kinase inhibitors)

RN 913001-79-3 CAPLUS


CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N2-[(1S)-1-cyclohexylethyl]-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913001-80-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5'-fluoro-2'-[(4-hydroxy-1-piperidinyl)carbonyl]-6-methyl- (CA INDEX NAME)




RN 913001-81-7 CAPLUS

CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-propyl- (CA INDEX NAME)




RN 913001-82-8 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N2-[2-(dimethylamino)ethyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)




RN 913001-83-9 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-84-0 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-(1-methylethyl)- (CA INDEX NAME)



RN 913001-85-1 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[(3-oxo-1-piperazinyl)carbonyl]- (CA INDEX NAME)



RN 913001-86-2 CAPLUS

CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-[(2S)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913001-87-3 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-[(2R)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913001-88-4 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl-N3'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913001-89-5 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-amino-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)



RN 913001-90-8 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-[(1S)-1,2-dimethylpropyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913001-91-9 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-[(1R)-1,2-dimethylpropyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913001-92-0 CAPLUS
 CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-(2-methylpropyl)-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-93-1 CAPLUS
 CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-(cyclopropylmethyl)-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-94-2 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-(3-methylbutyl)-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-95-3 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-N3'-(3,5-dimethyl-1H-pyrazol-4-yl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-96-4 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-1,2,4-thiadiazol-5-yl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-97-5 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-1H-pyrazol-3-yl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-98-6 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-(3-methyl-5-isothiazolyl)-N2-2-thiazolyl- (CA INDEX NAME)




RN 913001-99-7 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-3-isoxazolyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-00-3 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclohexyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-01-4 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2,N3'-bis(2-thiazolyl)- (CA INDEX NAME)



RN 913002-02-5 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N3'-phenyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-03-6 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl-N3'-[(1S)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 913002-04-7 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4,N4-diethyl-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-05-8 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl-N4-[(1S)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 913002-06-9 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2,N4-bis(2-thiazolyl)- (CA INDEX NAME)




RN 913002-08-1 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-phenyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-09-2 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclohexyl-N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-10-5 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl-N4-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 913002-11-6 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-1H-pyrazol-3-yl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-12-7 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(3,5-dimethyl-1H-pyrazol-4-yl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-13-8 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-1,2,4-thiadiazol-5-yl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-14-9 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[(1R)-1,2-dimethylpropyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913002-15-0 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[(1S)-1,2-dimethylpropyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913002-16-1 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(cyclopropylmethyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-17-2 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl-N4-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 913002-18-3 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-
N4-[(1R)-1-phenylethyl]-N2-2-thiazolyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913002-19-4 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-
N4-(phenylmethyl)-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-20-7 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(cyclohexylmethyl)-N3'-cyclopropyl-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-21-8 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-(2-methylpropyl)-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-22-9 CAPLUS
 CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[3-(dibutylamino)propyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-23-0 CAPLUS
 CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[3-(dimethylamino)-2,2-dimethylpropyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-24-1 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-(3-methylbutyl)-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-25-2 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(1-ethylpropyl)-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-26-3 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-[(3,4-dimethylphenyl)methyl]-5'-fluoro-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-27-4 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-N4,6'-dimethyl-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-28-5 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-5'-fluoro-6'-methyl-N4-[2-(1-pyrrolidinyl)ethyl]-N2-2-thiazolyl- (CA INDEX NAME)




RN 913002-29-6 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)




RN 913002-30-9 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-cyclopentyl-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)




RN 913002-31-0 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-(cyclohexylmethyl)-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)




RN 913002-32-1 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-phenyl- (CA INDEX NAME)



RN 913002-33-2 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N2-(3,4-difluorophenyl)-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-34-3 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-

dimethylpropyl)-5'-fluoro-N2-(4-fluorophenyl)-6'-methyl- (CA INDEX NAME)




RN 913002-35-4 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 913002-36-5 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-N2-(3-ethoxypropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)




RN 913002-37-6 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-(5-hydroxypentyl)-6'-methyl- (CA INDEX NAME)




RN 913002-38-7 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-N2-[3-(1H-imidazol-1-yl)propyl]-6'-methyl- (CA INDEX NAME)




RN 913002-39-8 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 913002-40-1 CAPLUS
 CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N2-[2-[4-(aminosulfonyl)phenyl]ethyl]-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)




RN 913002-41-2 CAPLUS
 CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N2-[3-(dibutylamino)propyl]-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)




RN 913002-42-3 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'--[4-(1-pyrrolidinyl)-1-piperidinylcarbonyl]- (CA INDEX NAME)




RN 913002-43-4 CAPLUS

CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-(4-phenylbutyl)- (CA INDEX NAME)



RN 913002-44-5 CAPLUS


CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N2-(5-cyanopentyl)-N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-45-6 CAPLUS


CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N3'-cyclopropyl-N4-(2,2-

dimethylpropyl)-5'-fluoro-6'-methyl-N2-(2-phenylethyl)- (CA INDEX NAME)




RN 913002-46-7 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)




RN 913002-47-8 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-5'-fluoro-6'-methyl-N2-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 913002-48-9 CAPLUS


CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-N2-[(1-ethyl-2-pyrrolidinyl)methyl]-5'-fluoro-6'-methyl- (CA INDEX NAME)



RN 913002-49-0 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-[(2S)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913002-50-3 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-[(2R)-2-hydroxypropyl]-6'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913002-51-4 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-[(1S)-1-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913002-52-5 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-


N3'-[(1R)-1-hydroxypropyl]-6'-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913002-53-6 CAPLUS

CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-
N3'-[(4-fluorophenyl)methyl]-6'-methyl- (CA INDEX NAME)




RN 913002-54-7 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5'-fluoro-6-methyl-2'-[[[(phenylmethyl)amino]carbonyl]amino]- (CA INDEX NAME)




RN 913002-58-1 CAPLUS


CN [1,1'-Biphenyl]-2,3',4'-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl- (CA INDEX NAME)




RN 913002-59-2 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl-N2-2-thiazolyl- (CA INDEX NAME)



RN 913002-60-5 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-N2-(3-hydroxypropyl)-6'-methyl- (CA INDEX NAME)




RN 913002-61-6 CAPLUS
CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl-N2-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 913002-62-7 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N3'-cyclopropyl-N4-(2,2-dimethylpropyl)-6'-methyl-N2-3-pyridinyl- (CA INDEX NAME)




RN 913002-64-9 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-N3'-(2-hydroxyethyl)-6'-methyl- (CA INDEX NAME)




RN 913002-65-0 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-(2-hydroxyethyl)-6'-methyl- (CA INDEX NAME)




RN 913002-66-1 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-(3-hydroxypropyl)-6'-methyl- (CA INDEX NAME)



RN 913002-67-2 CAPLUS

CN [1,1'-Biphenyl]-2,3',4-tricarboxamide, N4-(2,2-dimethylpropyl)-5'-fluoro-N3'-(3-hydroxypropyl)-6'-methyl-N3'-3-pyridinyl- (CA INDEX NAME)




IT 776315-27-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of biphenyldicarboxamides as p38 kinase inhibitors)



RN 776315-27-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-formyl-6-methyl- (CA INDEX NAME)



L6 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:927166 CAPLUS
 DOCUMENT NUMBER: 141:395428
 TITLE: Biarylmethyl indolines, indoles, and tetrahydroquinolines, useful as serine protease inhibitors, and particularly as anticoagulants, and their preparation, pharmaceutical compositions, and use.
 INVENTOR(S): Smallheer, Joanne M.; Quan, Mimi L.; Wang, Shuaige; Bisacchi, Gregory S.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094372	A2	20041104	WO 2004-US11856	20040415
WO 2004094372	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040220206	A1	20041104	US 2004-824025	20040414
US 7129264	B2	20061031		
EP 1633716	A2	20060315	EP 2004-750251	20040415
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2006523716	T	20061019	JP 2006-513080	20040415
PRIORITY APPLN. INFO.:			US 2003-463452P	P 20030416
			US 2004-824025	A 20040414
			WO 2004-US11856	W 20040415
OTHER SOURCE(S):	MARPAT 141:395428			
GI				



II

AB The invention provides compds. I or stereoisomers, pharmaceutically acceptable salts or hydrates, or prodrugs thereof [wherein: W = (un)substituted CH₂CH₂, CH:CH, CH:N, or CH₂CH₂CH₂; L₁ = CH₂, CH₂CH₂, CH₂S(O)0-2, or CH₂C(O); L₂ = bond, (un)substituted CH₂, CH₂CH₂, O, NH, C(O), S(O)0-2, CH₂C(O), C(O)CH₂, CH₂O, OCH₂, CH₂NH, NHCH₂, CH₂S(O)0-2, S(O)0-2CH₂, C(O)O, OC(O), C(O)NH, NHC(O), S(O)NH, S(O)2NH, NHS(O), or NHS(O)2; A = (un)substituted C₃-10 carbocycle or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; B = (un)substituted alk(en/yn)yl, C₃-10 carbocycle, or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; X = (independently) (un)substituted CH or N]. I are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, the invention relates to compds. that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compns. comprising I, and methods of treating thromboembolic and/or inflammatory disorders using I. I had K_i values of ≤ 15 μM in assays for Factor XIa and plasma kallikrein, thereby confirming their utility as effective inhibitors of these entities. Approx. 115 compds. I and various intermediates were prepared. For instance, 5-cyanoindole was reduced to 5-cyanoindoline with NaBH₃CN (40%) or with Et₃SiH (77%). Then, Suzuki coupling of 2-IC₆H₄CO₂Me with 2-OCHC₆H₄B(OH)₂ gave 83% 2-OCHC₆H₄-C₆H₄CO₂Me-2, which underwent reductive alkylation with 5-cyanoindoline (86%). The obtained 1-substituted 5-cyanoindoline was converted to the corresponding 5-amidoxime, which was reduced by Zn in AcOH to give the 5-amidine (18.5%). Alkaline saponification of the ester moiety gave invention compound II, isolated as the bis(trifluoroacetate) salt.

IT 787631-06-5P, 2'-{(3-Benzyl-5-carbamimidoylindol-1-yl)methyl}-4-


carbamoyl-5'-(methylcarbamoyl)biphenyl-2-carboxylic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biaryl methyl indolines, indoles, and tetrahydroquinolines as serine protease inhibitors and anticoagulants)

RN 787631-06-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-2'-[[5-(aminoininomethyl)-3-(phenylmethyl)-1H-indol-1-yl]methyl]-5'-[(methylamino)carbonyl]- (CA INDEX NAME)



L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:872774 CAPLUS

DOCUMENT NUMBER: 141:349930

TITLE: Preparation of biphenylcarboxylic amide derivatives as p38 kinase inhibitors

INVENTOR(S): Aston, Nicola Mary; Bamborough, Paul; Jones, Katherine Louise; Patel, Vipulkumar Kantibhai; Swanson, Stephen; Walker, Ann Louise

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089874	A1	20041021	WO 2004-EP3774	20040407
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,			

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG

AU 2004228199	A1	20041021	AU 2004-228199	20040407
CA 2521228	A1	20041021	CA 2004-2521228	20040407
EP 1608616	A1	20051228	EP 2004-726134	20040407


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004008727	A	20060307	BR 2004-8727	20040407
JP 2006523194	T	20061012	JP 2006-505071	20040407
MX 2005PA10521	A	20051214	MX 2005-PA10521	20050929
US 20070129354	A1	20070607	US 2005-551502	20050930


PRIORITY APPLN. INFO.: GB 2003-8186 A 20030409
 WO 2004-EP3774 A 20040407

OTHER SOURCE(S): MARPAT 141:349930

GI



I



II


AB Title compds. represented by the formula I [wherein R1 = H, alkenyl, (un)substituted (cyclo)alkyl, Ph, heteroaryl; R2 = H, (un)substituted alkyl, alkylcycloalkyl or R1R2 = (un)substituted (hetero)cyclic ring; R3 = Me or Cl; R4 = (un)substituted carbonylaminoalkyl, carbamoyl(alkyl); X, Y = independently H, Me, halo; Z = alkylhydroxy, alkylamino, alkyl, etc.; m = 0-4; n = 1; and pharmaceutically acceptable derivative thereof] were prepared as p38 kinase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of Me 3-hydroxy-4-iodobenzoate with 2-chloro-N,N-dimethylethylamine. I were tested for p38 inhibition in fluorescence anisotropy kinase binding assay with IC50 values of less than 10 μ M. Thus, I and their pharmaceutical compns. are useful as p38 kinase inhibitors for the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

IT 776313-96-3P 776313-97-4P 776313-99-6P
 776314-00-2P 776314-01-3P 776314-03-5P
 776314-44-4P 776314-68-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of biphenylcarboxylic amide derivs. as p38 kinase inhibitors)


RN 776313-96-3 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-(methoxymethoxy)-6-methyl- (CA INDEX NAME)




RN 776313-97-4 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-(methoxymethoxy)-6-methyl-N4'-(2-methylpropyl)- (CA INDEX NAME)




RN 776313-99-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-5-fluoro-2'-(methoxymethoxy)-6-methyl- (CA INDEX NAME)




RN 776314-00-2 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-(methoxymethoxy)-N4'-[(4-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)




RN 776314-01-3 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-(methoxymethoxy)-6-methyl-N4'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 776314-03-5 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-[(1R)-1,2-dimethylpropyl]-5-fluoro-2'-(methoxymethoxy)-6-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 776314-44-4 CAPLUS
 CN Butanoic acid, 4-[[5'-[(cyclopropylamino)carbonyl]-4-[[[(2,2-dimethylpropyl)amino]carbonyl]-3'-fluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]- (CA INDEX NAME)



RN 776314-68-2 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-amino-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)




IT 776313-93-0P 776313-95-2P 776314-06-8P
 776314-07-9P 776314-09-1P 776314-11-5P
 776314-13-7P 776314-15-9P 776314-16-0P
 776314-18-2P 776314-20-6P 776314-21-7P
 776314-22-8P 776314-23-9P 776314-25-1P
 776314-26-2P 776314-27-3P 776314-29-5P
 776314-31-9P 776314-33-1P 776314-35-3P
 776314-36-4P 776314-38-6P 776314-39-7P
 776314-41-1P 776314-46-6P 776314-48-8P
 776314-50-2P 776314-52-4P 776314-54-6P
 776314-56-8P 776314-58-0P 776314-60-4P
 776314-62-6P 776314-64-8P 776314-66-0P
 776314-70-6P 776314-72-8P 776314-74-0P
 776314-76-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biphenylcarboxylic amide derivs. as p38 kinase inhibitors)


RN 776313-93-0 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-2'-[2-(dimethylamino)ethoxy]-5-fluoro-6-methyl- (CA INDEX NAME)




RN 776313-95-2 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-6-methyl-N4'-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 776314-06-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-hydroxy-6-methyl- (CA INDEX NAME)




RN 776314-07-9 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-6-methyl-N4'-(2-methylpropyl)- (CA INDEX NAME)




RN 776314-09-1 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-5-fluoro-2'-hydroxy-6-methyl- (CA INDEX NAME)



RN 776314-11-5 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-N4'-[(4-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)



RN 776314-13-7 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-hydroxy-6-methyl-N4'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 776314-15-9 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-[(1R)-1,2-dimethylpropyl]-5-fluoro-2'-hydroxy-6-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 776314-16-0 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-methoxy-6-methyl- (CA INDEX NAME)




RN 776314-18-2 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-methoxy-6-methyl-N4'-(2-methylpropyl)- (CA INDEX NAME)




RN 776314-20-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-5-fluoro-2'-methoxy-6-methyl- (CA INDEX NAME)



RN 776314-21-7 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-methoxy-N4'-[(4-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)



RN 776314-22-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-5-fluoro-2'-methoxy-6-methyl-N4'-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 776314-23-9 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-[(1R)-1,2-dimethylpropyl]-5-fluoro-2'-methoxy-6-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 776314-25-1 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-propoxy- (CA INDEX NAME)




RN 776314-26-2 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-[3-(dimethylamino)propoxy]-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)




RN 776314-27-3 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-[3-(diethylamino)propoxy]-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)




RN 776314-29-5 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



RN 776314-31-9 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-[(1-methylethyl)amino]propoxy]- (CA INDEX NAME)




RN 776314-33-1 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[3-[(2-hydroxyethyl)amino]propoxy]-6-methyl- (CA INDEX NAME)




RN 776314-35-3 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-[methyl(1-methylethyl)amino]propoxy]- (CA INDEX NAME)




RN 776314-36-4 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)




RN 776314-38-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[2-[(methylsulfonyl)amino]ethoxy]- (CA INDEX NAME)




RN 776314-39-7 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 776314-41-1 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[2-(4-morpholinyl)-2-oxoethoxy]- (CA INDEX NAME)




RN 776314-46-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-(4-amino-4-oxobutoxy)-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)




RN 776314-48-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[4-(methylamino)-4-oxobutoxy]- (CA INDEX NAME)




RN 776314-50-2 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-[4-(dimethylamino)-4-oxobutoxy]-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl- (CA INDEX NAME)




RN 776314-52-4 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[4-(ethylamino)-4-oxobutoxy]-5-fluoro-6-methyl- (CA INDEX NAME)




RN 776314-54-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[4-oxo-4-(1-pyrrolidinyl)butoxy]- (CA INDEX NAME)




RN 776314-56-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[4-(4-morpholinyl)-4-oxobutoxy]- (CA INDEX NAME)




RN 776314-58-0 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-(4-hydroxybutoxy)-6-methyl- (CA INDEX NAME)




RN 776314-60-4 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-6-methyl-2'-[3-(1,3,4-oxadiazol-2-yl)propoxy]- (CA INDEX NAME)




RN 776314-62-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-2'-(2,3-dihydroxypropoxy)-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)




RN 776314-64-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[[2,2-dimethylpropyl)amino]methyl]-5-fluoro-6-methyl- (CA INDEX NAME)




RN 776314-66-0 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-(hydroxymethyl)-6-methyl- (CA INDEX NAME)




RN 776314-70-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[(1-oxopropyl)amino]- (CA INDEX NAME)




RN 776314-72-8 CAPLUS


CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-(acetylamino)-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)




RN 776314-74-0 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-2'-[(ethylamino)carbonylamino]-6-methyl- (CA INDEX NAME)



RN 776314-76-2 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-[(methylsulfonyl)amino]- (CA INDEX NAME)




IT 776315-01-6P 776315-20-9P 776315-21-0P
 776315-27-6P 776315-29-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of biphenylcarboxylic amide derivs. as p38 kinase inhibitors)
 RN 776315-01-6 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxamide, 2'-(3-bromopropoxy)-N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl- (CA INDEX NAME)




RN 776315-20-9 CAPLUS

CN Hydrazinecarboxylic acid, 2-[4-[[5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-3'-fluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]-1-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 776315-21-0 CAPLUS

CN Butanoic acid, 4-[[5'-[(cyclopropylamino)carbonyl]-4-[[(2,2-dimethylpropyl)amino]carbonyl]-3'-fluoro-2'-methyl[1,1'-biphenyl]-2-yl]oxy]-, hydrazide (CA INDEX NAME)




RN 776315-27-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-5-fluoro-2'-formyl-6-methyl- (CA INDEX NAME)



RN 776315-29-8 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(2,2-dimethylpropyl)-6-methyl-2'-nitro- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:780670 CAPLUS

DOCUMENT NUMBER: 141:295874

TITLE: Preparation of tetrahydroquinoline derivatives as

inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system. Quan, Mimi L.; Wang, Cailan; Zhou, Jinglan; Hangeland, Jon J.; Seiffert, Dietmar A.; Knabb, Robert M.

INVENTOR(S):

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080971	A1	20040923	WO 2004-US7216	20040310
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040235847	A1	20041125	US 2004-796396	20040309
US 7138412	B2	20061121		
EP 1601656	A1	20051207	EP 2004-719245	20040310
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
JP 2006519844	T	20060831	JP 2006-507012	20040310
US 20060223854	A1	20061005	US 2006-430588	20060509
PRIORITY APPLN. INFO.:			US 2003-453812P	P 20030311
			US 2004-796396	A 20040309
			WO 2004-US7216	W 20040310

OTHER SOURCE(S): MARPAT 141:295874

GI




AB Title compds. [I; L1 = bond, CH2, CH2CH2, CH2O, CH2CO, etc.; L2 = bond, O, CO, CO2, S, SO, SO2, CONR8, SO2NR8, etc.; A = (substituted) carbocyclylene, heterocyclylene; B = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl; X1-X4 = CR1, CR2, N, etc.; R1 = H, F, Cl, Br, iodo, OCF3, CF3, cyano, NH2, alkylamino, dialkylamino, CONH2, CH2CH2NH2, etc.; R2 = H, F, Cl, Br, iodo, OCF3, CF3, cyano, NO2, amino, aminocarbonyl, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; R3 = H, F, haloalkyl, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; R4 = H, F, haloalkyl, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; R5 = H, F, haloalkyl, (substituted) alkyl, alkenyl, alkynyl, heterocyclyl(alkyl), etc.; R13 = H, F, alkyl, aminoalkyl, CF3, aminocarbonyl, etc.; R14 = H, alkyl, aminoalkyl, F, CF3, aminocarbonyl, etc.; R13R14 = O; R15 = H, alkyl; R16 = H, alkyl, PhCH2, alkylcarbonyl, alkylsulfonyl, alkoxycarbonyl], were prepared. Thus, 4-amidinobenzamidine monohydrochloride, styrene, 1'-formyl-1-benzoyloxycarbonyl-4-isobutylcarbonylbiphenyl (preparation given) and indium triflate were heated together at 70° in MeCN for 12 h to give a product which was hydrogenolyzed in MeOH/HOAc over Pd/C to give 2'-(6-carbamimidoyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl)-4-isobutylcarbonylbiphenyl-2-carboxylic acid. I inhibited Factor XIa with $K_i \leq 15 \mu M$.

IT 762253-64-5P 762253-65-6P 762253-68-9P
762253-69-0P 762253-70-3P 762253-71-4P
762253-73-6P 762253-76-9P 762253-77-0P
762253-78-1P 762253-79-2P 762253-80-5P
762253-81-6P 762253-82-7P 762253-83-8P
762253-84-9P 762253-86-1P 762253-87-2P
762253-88-3P 762253-89-4P 762253-91-8P
762253-92-9P 762253-93-0P 762253-94-1P
762253-95-2P 762253-96-3P 762253-97-4P
762254-16-0P 762254-17-1P 762254-19-3P
762254-69-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of carbaminidoyletetrahydroquinoline derivs. as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system)

RN 762253-64-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-(acetylamino)-4-(aminocarbonyl)-5'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]- (CA INDEX NAME)




RN 762253-65-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]- (CA INDEX NAME)




RN 762253-68-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]- (CA INDEX NAME)




RN 762253-69-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)




RN 762253-70-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(1-oxopropyl)amino]- (CA INDEX NAME)




RN 762253-71-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(cyclopropylcarbonyl)amino]- (CA INDEX NAME)




RN 762253-73-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(1-oxobutyl)amino]- (CA INDEX NAME)




RN 762253-76-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-carboxyacetyl)amino]- (CA INDEX NAME)




RN 762253-77-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(carboxycarbonyl)amino]- (CA INDEX NAME)




RN 762253-78-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-(benzoylamino)- (CA INDEX NAME)




RN 762253-79-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-phenylacetyl)amino]- (CA INDEX NAME)




RN 762253-80-5 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-4-(4-fluorophenyl)-1,2,3,4-tetrahydro-4-methyl-2-quinolinyl]-5'-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)




RN 762253-81-6 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-carboxy-1-oxopropyl)amino]- (CA INDEX NAME)




RN 762253-82-7 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(4-carboxybenzoyl)amino]- (CA INDEX NAME)



RN 762253-83-8 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-carboxybenzoyl)amino]- (CA INDEX NAME)




RN 762253-84-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2-carboxybenzoyl)amino]- (CA INDEX NAME)




RN 762253-86-1 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[[[4'-(aminocarbonyl)-5-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-2'-carboxy[1,1'-biphenyl]-3-yl]amino]carbonyl]- (CA INDEX NAME)




RN 762253-87-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[2-(2H-tetrazol-5-yl)acetyl]amino]- (CA INDEX NAME)




RN 762253-88-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(4-carboxy-1-oxobutyl)amino]- (CA INDEX NAME)




RN 762253-89-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(2H-tetrazol-5-ylcarbonyl)amino]- (CA INDEX NAME)




RN 762253-93-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[1-oxo-3-(2H-tetrazol-5-yl)propyl]amino]- (CA INDEX NAME)




RN 762253-94-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-carboxy-5-methylbenzoyl)amino]- (CA INDEX NAME)




RN 762253-95-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminocarbonyl)-5-carboxybenzoylamino]-5'-[[3-carboxy-5-(1,1-dimethylethyl)benzoylamino]- (CA INDEX NAME)



RN 762253-96-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[[3-(aminocarbonyl)-5-carboxybenzoylamino]-5'-[6-(aminocarbonyl)-5-carboxybenzoylamino]-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]- (CA INDEX NAME)



RN 762253-97-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[ethylamino]carbonylamino]- (CA INDEX NAME)




RN 762254-16-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-(acetylamino)-4-(aminocarbonyl)-5'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 762253-64-5

CMF C33 H31 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 762254-17-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 762253-65-6

CMF C36 H37 N5 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 762254-19-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[(3-methyl-1-oxobutyl)amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 762253-68-9
 CMF C36 H38 N4 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 762254-69-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[6-(aminoiminomethyl)-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinolinyl]-5'-[[3,5-bis(trifluoromethyl)benzoyl]amino]- (CA INDEX NAME)




IT 762254-61-5P 762254-62-6P 762254-67-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carbaminidoyletetrahydroquinoline derivs. as inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system)


RN 762254-61-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-(acetylamino)-4-(aminocarbonyl)-5'-[1,2,3,4-tetrahydro-4-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)-4-phenyl-2-quinolinyl]-, phenylmethyl ester (CA INDEX NAME)




RN 762254-62-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-[(3-methyl-1-oxobutyl)amino]-5'-[1,2,3,4-tetrahydro-4-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)-4-phenyl-2-quinolinyl]-, phenylmethyl ester (CA INDEX NAME)



RN 762254-67-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4-(aminocarbonyl)-3'-(6-cyano-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-quinoliny)-5'-[(3-methyl-1-oxobutyl)amino]-, phenylmethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:319702 CAPLUS

DOCUMENT NUMBER: 138:337841

TITLE: Preparation of 5'-carbamoyl-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors

INVENTOR(S): Angell, Richard Martyn; Aston, Nicola Mary; Bamborough, Paul; Bamford, Mark James; Cockerill, George Stuart; Merrick, Suzanne Joy; Smith, Kathryn Jane; Walker, Ann Louise

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----


WO 2003032972 A1 20030424 WO 2002-EP11577 20021016
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002362895 A1 20030428 AU 2002-362895 20021016
 EP 1435936 A1 20040714 EP 2002-801339 20021016
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005511532 T 20050428 JP 2003-535776 20021016
 US 20040267012 A1 20041230 US 2004-492698 20040415
 US 7208629 B2 20070424

PRIORITY APPLN. INFO.:


GB 2001-24941 A 20011017
 WO 2002-EP11577 W 20021016

OTHER SOURCE(S): MARPAT 138:337841

GI



I



II

AB The title compds. [I; when m = 0-4, R1 = alkyl, cycloalkyl, alkenyl, etc.; and when m = 2-4, R1 addnl. = alkoxy, OH, etc.; R2 = H, alkyl, (CH2)ncycloalkyl; R3 = CONH(CH2)pR6; R6 = H, alkyl, cycloalkyl, etc.; U = Me, halo; W = Me, Cl; V, Y = H, Me, halo; m = 0-4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from alkyl; n = 0-3; p = 0-2; s = 0-2], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepared E.g., a 3-step synthesis of the carboxamide II, starting from cyclopropylmethylamine and 4-bromobenzoyl chloride, was given.


IT 515135-12-3P 515135-23-6P 515135-24-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5'-carbamoyl-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors)


RN 515135-12-3 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-2',6-dimethyl- (CA INDEX NAME)




RN 515135-23-6 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-3'-fluoro-6-methyl- (CA INDEX NAME)



RN 515135-24-7 CAPLUS

CN [1,1'-Biphenyl]-3,4'-dicarboxamide, N3-cyclopropyl-N4'-(cyclopropylmethyl)-2'-fluoro-6-methyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:107059 CAPLUS

DOCUMENT NUMBER: 136:151182

TITLE: Antimicrobial biaryl compounds

INVENTOR(S): Jefferson, Elizabeth Ann; Swayze, Eric

PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009648	A2	20020207	WO 2001-US24067	20010801
WO 2002009648	A3	20020627		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 6849660	B1	20050201	US 2000-630122	20000801
CA 2418121	A1	20020207	CA 2001-2418121	20010801
AU 2001080944	A	20020213	AU 2001-80944	20010801
EP 1305028	A2	20030502	EP 2001-959380	20010801
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004519421	T	20040702	JP 2002-515203	20010801
PRIORITY APPLN. INFO.:			US 2000-630122	A 20000801
			WO 2001-US24067	W 20010801
OTHER SOURCE(S):	MARPAT	136:151182		
GI				



AB Biaryls I [X = CH, O, S, N, NH; Y = CH, N; n = 0, 1; one of R1 and R2 = (un)substituted CONR₂, COQNH₂, CH₂NH₂, SO₂NH₂ and the other is H or R₃; one of R5 and R6 = NHCOR₇, NHSO₂R₇, NHS(O)R₇ and the other is H, R₄; Q = amino acid or peptide residue; R₃ = H, halogen, (un)substituted NH₂, NHCOR₇; R₄ = H, halogen, hydroxyl, amino, carboxyl, alkyl, alkenyl, alkynyl; R₇ = H, amino, (un)substituted alkyl, alkenyl, alkynyl, 5-16 member carbocycle or heterocycle] were prepred for use as antimicrobial agents. Thus, polymer-supported piperazine was acylated with 5-bromo-2-thiophenecarboxylic acid, coupled with 3-H₂NC₆H₄B(OH)₂, and

acylated with 2,3-dioxobenzopyrazine-6-carboxylic acid to give the biaryl II. In a coupled bacterial transcription-translation assay II had an IC₅₀ of 25 μ M.

IT 395647-86-6P 395647-90-2P 395647-95-7P


395647-97-9P 395647-98-0P 395648-04-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylaminobiarylcarboxamides as bactericides)


RN 395647-86-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-[4-(aminocarbonyl)-3'-[(4-piperidinylcarbonyl)amino][1,1'-biphenyl]-2-yl]-1-ethyl-1,4-dihydro-7-methyl-4-oxo- (CA INDEX NAME)




RN 395647-90-2 CAPLUS

CN 1,3-Benzenedicarboxamide, N1-[4'-(aminocarbonyl)-2'-[[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl]amino][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 395647-95-7 CAPLUS


CN 1,3-Benzenedicarboxamide, N1-[2'-amino-4'-(aminocarbonyl)[1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 395647-97-9 CAPLUS
 CN 1(2H)-Pyrimidineacetamide, 4-amino-N-[4-(aminocarbonyl)-3'-[(4-piperidinylcarbonyl)amino][1,1'-biphenyl]-2-yl]-2-oxo- (CA INDEX NAME)




RN 395647-98-0 CAPLUS
 CN 1H-Purine-1-acetamide, 6-amino-N-[4'-(aminocarbonyl)-2'-[(2-hydroxyacetyl)amino][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



RN 395648-04-1 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, 3'-[[[(2S)-2-amino-3-hydroxy-1-oxopropylamino]-2-[(2-hydroxyacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:767018 CAPLUS
Correction of: 1996:672852

DOCUMENT NUMBER: 135:273074
Correction of: 126:31466

TITLE: Boronic acid and ester inhibitors of thrombin
INVENTOR(S): Amparo, Eugene C.; Miller, William H.; Pacofsky, Gregory J.; Wityak, John; Weber, Patricia C.; Duncia, John J. V.; Santella, Joseph B., III

PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, USA
SOURCE: U.S., 170 pp., Cont.-in-part of U.S. Ser. No. 348,029.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5563127	A	19961008	US 1994-364338	19941227
CA 2208971	A1	19960711	CA 1995-2208971	19951213
CA 2208971	C	20010116		
WO 9620689	A2	19960711	WO 1995-US16248	19951213
WO 9620689	A3	19961024		
W: AU, CA, JP, MX, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9646404	A	19960724	AU 1996-46404	19951213
EP 810858	A2	19971210	EP 1995-944331	19951213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
ZA 9510978	A	19970627	ZA 1995-10978	19951227
US 5698538	A	19971216	US 1996-690220	19960726
PRIORITY APPLN. INFO.:				US 1993-36377 B2 19930324
				US 1994-318029 B2 19941004
				US 1994-348029 A2 19941201
				US 1994-364338 A 19941227
				WO 1995-US16248 W 19951213

AB Novel boronic acid and ester and carboxyl-modified amino acid compds.
R1-Z-CHR2-A (A = organoboryl, BY1Y2; Y1, Y2 = independently OH, F, organoamino, C1-8 alkoxy, Y1Y2 = cyclic boron ester, amide containing N, S, O; etc.; Z = (CH2)mCX, X = amido, thioamido, etc., substituted C1-12 alkyl, alkenyl, etc.; R1 = arylalkenyl, aryl = substituted Ph, naphthyl,

biphenyl, etc.; R2 = substituted C1-12 alkyl, alkenyl, etc.), which are inhibitors of trypsin-like enzymes, are disclosed. Thus, amino acid modified boronic ester (Y1Y2 = (+)-pinanediol) was prepared in multiple steps starting from (+)-pinanediol 4-bromo-1(R)-(4-phenylbenzoyl)aminobutane-1-boronate. Thrombin inhibition activity of some of the compds. prepared is described.


IT 180897-16-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid-modified boronic acids and esters as inhibitors of thrombin)

RN 180897-16-9 CAPLUS

CN Carbamic acid, [4'-[[[(1R)-4-[(aminoiminomethyl)amino]-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl]amino]carbonyl]-3'-methyl[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:693143 CAPLUS

DOCUMENT NUMBER: 135:238672

TITLE: Functional radiographic imaging methods and agents

INVENTOR(S): Salb, Jesse; Cairns, Nick

PATENT ASSIGNEE(S): Veritas Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE: Patent


FAMILY ACC. NUM. COUNT: English

PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068151	A2	20010920	WO 2001-US8612	20010315
WO 2001068151	A3	20021010		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6226352 B1 20010501 US 1998-149734 19980908
 WO 2000013590 A2 20000316 WO 1999-US20298 19990831
 WO 2000013590 A3 20000720
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 JP 2002524126 T 20020806 JP 2000-568401 19990831
 US 20010001011 A1 20010510 US 2000-752619 20001229
 US 6923950 B2 20050802
 US 20010031035 A1 20011018 US 2001-809870 20010315
 US 6723746 B2 20040420
 EP 1263478 A2 20021211 EP 2001-920486 20010315
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 20030091508 A1 20030515 US 2002-279811 20020614
 US 20040170561 A1 20040902 US 2004-792155 20040302
 PRIORITY APPLN. INFO.: US 2000-190323P P 20000316
 US 1998-149734 A 19980908
 WO 1999-US20298 W 19990831
 US 2000-752619 A1 20001229
 US 2001-809870 A1 20010315
 WO 2001-US8612 W 20010315
 OTHER SOURCE(S): MARPAT 135:238672
 AB Systems and methods for radiog. imaging of tissue using a radio-opaque imaging agent that in one embodiment accumulates intracellularly in tissue in proportion to its functional, or physiol., activity. In one embodiment, the imaging agent is a cell membrane-permeable, radio-opaque, high affinity ligand for an intracellular target. The imaging agent is administered to a patient, and after an accumulation interval, radiog. images are acquired. The imaging agent preferentially accumulates in certain types of tissue and increases its radio-opacity. The tissue being examined is transilluminated by X-ray beams with preselected different mean energy spectra, and a sep. radiog. image is acquired during transillumination by each beam. An image processing system may perform a weighted combination of the acquired images to produce a single displayed image. The system and method thus provides a functional image displayed with the anatomical detail and spatial resolution of a radiog. image. Functional and anatomical information are displayed in complete registration, facilitating localization of abnormal tissue in relation to nearby anatomical structures. An example of an application is the use of 123I-labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase and localization of malignant tissue, and in particular, breast cancer. The application may be further extended to imaging of nucleic acids and fatty acids in malignant tissues as well as other abnormal tissues.
 IT 360779-16-4P 360779-17-5P 360779-20-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT




IT 360779-21-1P 360779-25-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(functional radiog. imaging: 123I-labeled derivs. of
triiodophenylbenzoyl-D-glucosamine for targeting hexokinase)

RN 360779-21-1 CAPLUS

CN D-Glucose, 2-[[[3',5'-bis(acetylmethylamino)-3,5-diamino-2',4',6'-
triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 360779-25-5 CAPLUS


CN D-Glucose, 2-[[[3-amino-3',5'-bis[[[(2,3-dihydroxypropyl)methylamino]carbon
yl]-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy- (CA
INDEX NAME)

Absolute stereochemistry.




IT 360779-26-6P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (functional radiog. imaging: ^{123}I -labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase)
 RN 360779-26-6 CAPLUS
 CN D-Glucose, 2-[[[3',5'-bis(acetylamino)-3-amino-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonylamino]-2-deoxy-, labeled with iodine-123 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




IT 360779-27-7 360779-28-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (functional radiog. imaging: ^{123}I -labeled derivs. of triiodophenylbenzoyl-D-glucosamine for targeting hexokinase)
 RN 360779-27-7 CAPLUS
 CN D-Glucose, 2-[[[3',5'-bis(acetylmethylamino)-3-amino-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonylamino]-2-deoxy-, labeled with iodine-123 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 360779-28-8 CAPLUS
 CN D-Glucose, 2-[[[3-amino-3',5'-bis[[2,3-dihydroxypropyl)methylamino]carbonyl]-2',4',6'-triiodo[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-deoxy-, labeled with iodine-123 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:529128 CAPLUS
 DOCUMENT NUMBER: 131:184864
 TITLE: Preparation of amidinophenylcarbonylbiphenyl derivatives and heterocyclic analogs thereof as inhibitors of blood coagulation factor VIIa
 INVENTOR(S): Senokuchi, Kazuhiko; Ogawa, Koji
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 665 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 9941231          A1      19990819      WO 1999-JP622          19990212
W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
    DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
    KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
    NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
    UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
    FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
    CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9923006          A      19990830      AU 1999-23006          19990212
EP 1078917          A1      20010228      EP 1999-902896        19990212
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, FI
ZA 9901273          A      19990825      ZA 1999-1273          19990217
US 6358960          B1      20020319      US 2000-601998        20000811
PRIORITY APPLN. INFO.:      JP 1998-76815          A      19980217
                                WO 1999-JP622          W      19990212


OTHER SOURCE(S):      MARPAT 131:184864
GI

```



AB The title compds. I [T1 = (R5)q; T2 = (R7)n; T3 = (R6)m; T4 = (R4)p; R1, R2 = H, alkoxy carbonyl, etc.; a proviso is given; R3 = H, alkyl, etc.; ring E1 = unsatd. heterocyclic ring, etc.; ring E2 = unsatd. heterocyclic ring, etc.; ring E3 = unsatd. or saturated heterocyclic ring, etc.; ring E3 may be omitted; ring E4 = unsatd. heterocyclic ring, etc.; R4, R5 = CO2R8, etc.; R8 = H, alkyl, etc.; p, q = 0, or 1, 2; p + q = 1 or 2; R6, R7 = H, alkyl, etc.; m = 1 - 3; n = 1 - 3] are prepared. I are useful as preventives and/or remedies for various vascular lesions associating accelerated coagulation activity, for example, universal intravascular coagulation syndrome, coronary thrombosis, brain infarction, brain embolism, transient cerebral ischemic attack, diseases associating cerebral vascular disorders, deep vein thrombosis, peripheral embolism, thrombus formation following artificial blood vessel operation or artificial valve replacement, diseases associating postoperative thrombus formation, reobstruction and reconstruction following coronary artery bypass, reobstruction and reconstruction following PTCA or PTCR, thrombus formation during extracorporeal circulation and glomerulonephritis. Formulations containing a compound of this invention are given. In an in vitro test, 2-[2-(4-amidinophenylcarbamoyl)-6-methoxy-3-pyridyl]-5-[(1(S)-hydroxymethyl-2,2-dimethylpropyl)carbamoyl]benzoic acid methanesulfonic acid salt showed IC50 of 0.013 μ M against factor VIIa.

IT 239458-88-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amidinophenylcarbamoylebiphenyl derivs. and heterocyclic analogs thereof as inhibitors of blood coagulation factor VIIa)
 RN 239458-88-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-4-[[[(2,2-dimethylpropyl)amino]carbonyl]-5'-[[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:299335 CAPLUS

DOCUMENT NUMBER: 129:28282

ORIGINAL REFERENCE NO.: 129:6037a,6040a

TITLE: Preparation and absorption spectrum studies of aromatic and alicyclic poly(amide acid) ammonium salts in water and DMF and in films

AUTHOR(S): Li, Qinghua; Yamashita, Takashi; Horie, Kazuyuki; Yoshimoto, Hiroshi; Miwa, Takao; Maekawa, Yasunari

CORPORATE SOURCE: Department of Chemistry and Biotechnology, Graduate School of Engineering, University of Tokyo, Tokyo, 113-8656, Japan

SOURCE: Journal of Polymer Science, Part A: Polymer Chemistry (1998), 36(8), 1329-1340
 CODEN: JPACEC; ISSN: 0887-624X

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of ammonium salts of poly(amide acid)s (PAS) were prepared from various poly(amide acid)s (PAA) with tertiary amines. The solubility of poly-(amide acid) ammonium salts prepared from PAA(PMDA/ODA) in water is related to the ion concentration of tertiary amines. In order to elucidate the influence of the chemical structures of poly(amide acid)s and poly(amide acid) ammonium salts on their absorption spectra, pyromellitic dianhydride (PMDA), 3,3',4,4'-biphenyltetracarboxylic dianhydride (BPDA), and

3,3',4,4'-benzophenonetetracarboxylic dianhydride (BTDA) were chosen to react with p-phenylenediamine (PDA) and (4,4'-diaminodicyclohexyl)methane (DCHM) to give three kinds of aromatic PAAs and three kinds of alicyclic PAAs. The corresponding PASs were prepared by the reaction of PAAs with triethanolamine (TEA). Their UV-visible (UV-vis) absorption spectra were investigated compared to those of model compds. A transparent film without absorption above 320 nm was obtained for PAS (PMDA/DCHM). The difference in absorption spectra of PAS(PMDA/PDA) from that of PAS(PMDA/DCHM) can be related to the existence of intra- and intermol. charge transfer (CT) for PAS(PMDA/PDA). The absorption spectra of PASs with PDA in films are red shifted compared to those of corresponding PAAs in films, while the absorption spectra of PASs in water are blue shifted compared to those of corresponding PAAs in DMF. No differences in the absorption spectra of PAAs and PASs were found in DMF/H₂O (9/1) mixed solvent.


IT 207921-92-4P 207921-93-5P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(model compound; preparation and absorption spectrum studies of aromatic and alicyclic polyamic acid ammonium salts in water and DMF and in films)


RN 207921-92-4 CAPLUS

CN [1,1'-Biphenyl]-3,3',4,4'-tetracarboxamide, N3,N3',N4,N4'-tetraphenyl-
(CA INDEX NAME)



RN 207921-93-5 CAPLUS

CN [1,1'-Biphenyl]-3,3',4,4'-tetracarboxamide, N3,N3',N4,N4'-tetracyclohexyl-
(CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:672852 CAPLUS

DOCUMENT NUMBER: 126:31466

ORIGINAL REFERENCE NO.: 126:6405a,6408a

TITLE: Boronic acid and ester inhibitors of thrombin
INVENTOR(S): Amparo, Eugene C.; Miller, William H.; Pacofsky, Gregory J.; Wityak, John; Weber, Patricia C.; Duncia, John J. V.; Santella, Joseph B., III

PATENT ASSIGNEE(S): The Dupont Merck Pharmaceutical Company, USA


SOURCE: U.S., 170 pp., Cont.-in-part of U.S. Ser. No. 348,029.

DOCUMENT TYPE: CODEN: USXXAM

LANGUAGE: Patent


PATENT INFORMATION: English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5563127 A		19961008	US 1994-364338	19941227
PRIORITY APPLN. INFO.:			US 1993-36377	19930324
			US 1994-318029	19941004
			US 1994-348029	19941201
OTHER SOURCE(S):		MARPAT 126:31466		
GI				



- AB Novel boronic acid and ester and carboxyl-modified amino acid compds.
 R1-Z-CHR2-A (A = organoboryl, BY1Y2; Y1, Y2 = independently OH, F, organoamino, C1-8 alkoxy, Y1Y2 = cyclic boron ester, amide containing N, S, O; etc.; Z = (CH2)mCX, X = amido, thioamido, etc., substituted C1-12 alkyl, alkenyl, etc.; R1 = arylalkenyl, aryl = substituted Ph, naphthyl, biphenyl, etc.; R2 = substituted C1-12 alkyl, alkenyl, etc.), which are inhibitors of trypsin-like enzymes, are disclosed. Thus, amino acid modified boronic ester I (Y1Y2 = (+)-pinanediol) was prepared in multiple steps starting from (+)-pinanediol 4-bromo-1(R)-(4-phenylbenzoyl)aminobutane-1-boronate. Thrombin inhibition activity of some of the compds. prepared is described.
- IT 180897-16-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amino acid-modified boronic acids and esters as inhibitors of thrombin)
- RN 180897-16-9 CAPLUS
- CN Carbamic acid, [4'-[[[(1R)-4-[(aminoiminomethyl)amino]-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl]amino]carbonyl]-3'-methyl[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:557907 CAPLUS

DOCUMENT NUMBER: 125:222432

ORIGINAL REFERENCE NO.: 125:41597a,41600a

TITLE: Preparation of α -aminoboronic acid and ester as inhibitors of thrombin

INVENTOR(S): Amparo, Eugene Cruz; Miller, William Henry; Pacofsky, Gregory James; Wityak, John; Weber, Patricia Carol; Duncia, John Jonas Vytutas; Santella, Joseph Basil, III

PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 416 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620689	A2	19960711	WO 1995-US16248	19951213
WO 9620689	A3	19961024		
W: AU, CA, JP, MX, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5563127	A	19961008	US 1994-364338	19941227
AU 9646404	A	19960724	AU 1996-46404	19951213
EP 810858	A2	19971210	EP 1995-944331	19951213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
PRIORITY APPLN. INFO.:				
			US 1994-364338	A 19941227
			US 1993-36377	B2 19930324
			US 1994-318029	B2 19941004
			US 1994-348029	A2 19941201
			WO 1995-US16248	W 19951213

OTHER SOURCE(S): MARPAT 125:222432

AB Novel boronic acid and ester and carboxyl-modified amino acid compds. of formula R1-Z-CH(R1)-A [A = BY1Y2, CO CF3, CO2R3, COCOR3, CO3H2, CHO, etc.; wherein Y1, Y2 = OH, F, NR3R4, C1-8 alkoxy; or Y1 and Y2 are taken together to form a cyclic boron ester, cyclic boron amide, or cyclic boron amide ester containing 2-20 C atoms and 0-3 heteroatoms selected from N, S, or Se; R3 = H, C1-8 alkyl, aryl-C1-4 alkyl, C5-7 cycloalkyl, Ph; R4 = group listed in R3, phenylsulfonyl; Z = (CH2)m CON R8, (CH2)m C(S)NR8, (CH2)m CO2, (CH2)m C(S)O, (CH2)m SO2O; wherein m = 0-6 and R8 = H, ring-(un)substituted phenylalkyl, C3-7 cycloalkyl, C1-8 alkyl; R1 = ring-substituted arylalkyl or heteroaryl, etc.; R2 = substituted C1-12 alkyl or C2-12 alkenyl, (substituted alkyl)phenylalkyl], which are inhibitors of trypsin-like enzymes, notably blood coagulation proteases such as human thrombin, factor VIIa, factor IXa, factor Xa, plasma kallikrein, and plasmin, and are useful for the treatment of thrombosis and inflammation or as anticoagulants for the processing of blood for therapeutic or diagnostic purposes or for the production of blood products or fragments, are prepared. Thus, (+)-pinanediol 4-bromo-1(R)-aminobutane-1-boronate hydrochloride was acylated by 4-phenylbenzoyl chloride in the presence of N-methylmorpholine in CH2Cl2 to give (+)-pinanediol 4-bromo-1(R)-(4-phenylbenzoylamino)butane-1-boronate, which underwent azidolysis with NaN3 in DMF at 70° for 2 h to give (+)-pinanediol 4-azido-1(R)-(4-phenylbenzoylamino)butane-1-boronate, and catalytic hydrogenation in the presence of Pd(OH)2/C in a mixture of MeOH and 1 M aqueous HCl to give (+)-pinanediol 4-amino-1(R)-(4-phenylbenzoylamino)butane-1-boronate, i.e., N1-(4-phenylbenzoyl)boroornithine (+)-pinanediol ester hydrochloride, followed by condensation with aminoiminomethanesulfonic acid in the presence of 4-dimethylaminopyridine in ethanol at reflux of 3 h to give N-(4-phenylbenzoyl)boroarginine (+)-pinanediol ester, bisulfite. The latter compound in vitro inhibited human thrombin and factor Xa with Ki value of <500 and 50,000 nM, resp.


IT 180897-16-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of α-aminoboronic acids and esters as inhibitors of blood coagulation proteases for disease therapy)

RN 180897-16-9 CAPLUS

CN Carbamic acid, [4'-[[(1R)-4-[(aminoiminomethyl)amino]-1-[(3aS,4S,6S,7aR)-

hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl]amino]carbonyl]-3'-methyl[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:340537 CAPLUS

DOCUMENT NUMBER: 122:134119

ORIGINAL REFERENCE NO.: 122:25027a,25030a

TITLE: Manufacture of silicon-containing polyfunctional carboxylic acid amides and their curing materials with good hardness and adhesion

INVENTOR(S): Kunimune, Koichi; Aono, Toshiharu; Watanabe, Eiji

PATENT ASSIGNEE(S): Chisso Corp, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06157556	A	19940603	JP 1992-255571	19920831
JP 3626214	B2	20050302		

PRIORITY APPLN. INFO.: JP 1992-255571 19920831

AB The amides are prepared by the reaction of silanes and polyfunctional carboxylic acids. Reaction of aminophenyltrimethoxysilane and 3,3',4,4'-benzophenonetetracarboxylic dianhydride, dehydration, coating on a wafer, and curing gave samples showed good adhesion and pencil hardness ≥ 9 H.

IT 160767-12-4P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(manufacture of silicon-containing polyfunctional carboxylic acid amides and their curing materials with good hardness and adhesion)


RN 160767-12-4 CAPLUS

CN [1,1'-Biphenyl]-3,3',4,4'-tetracarboxamide, N,N',N'',N'''-tetrakis(trimethoxysilyl)phenyl]-, homopolymer (9CI) (CA INDEX NAME)


CM 1

CRN 344800-32-4
 CMF C52 H62 N4 O16 Si4
 CCI IDS

PAGE 1-A



PAGE 2-A



L6 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:76159 CAPLUS

DOCUMENT NUMBER: 108:76159

ORIGINAL REFERENCE NO.: 108:12615a,12618a

TITLE: Proton NMR spectroscopic study of the isomeric composition of aromatic polyamic acids

AUTHOR(S): El'mesov, A. N.; Bogachev, Yu. S.; Zhuravleva, I. L.; Kardash, I. E.

CORPORATE SOURCE: Fiz.-Khim. Inst. im. Karpova, Moscow, USSR

SOURCE: Vysokomolekulyarnye Soedineniya, Seriya A (1987), 29(11), 2333-9

CODEN: VYSAAF; ISSN: 0507-5475

DOCUMENT TYPE: Journal


LANGUAGE: Russian

AB NMR spectroscopy of a series of polyamic acids prepared by polycondensation of dianhydrides of different aromatic tetracarboxylic acids (3,3',4,4'-diphenyl sulfone tetracarboxylic dianhydride,

3,3',4,4'-benzophenonetetracarboxylic dianhydride, 3,3',4,4'-diphenyltetracarboxylic dianhydride, 3,3',4,4'-diphenyl oxide tetracarboxylic dianhydride) with different diamines (p-phenylenediamine, p-benzidine, 4,4'-diaminodiphenylmethane, 4,4'-diaminodiphenyl oxide, 4,4'-diaminodiphenyl sulfone) showed that the isomer composition of the products depended on the nature of the bridge unit in the dianhydride. The presence of electron-acceptor units in the dianhydride led to enrichment of the polymer by m-isomer structures, whereas units with electron-donor properties increased the concentration of p-isomer in the polymer.

In the case of lack of a bridge unit, approx. equal. amts. of both isomers were formed. The chemical structure of the diamines did not affect significantly the isomer composition of the polyamic acids.

IT 112824-09-6
 RL: PRP (Properties)
 (structure of, as model for aromatic polyamic acids)
 RN 112824-09-6 CAPLUS
 CN [1,1'-Biphenyl]-3,4'-dicarboxylic acid, 3',4-bis[[4-methoxyphenyl]amino]carbonyl]- (CA INDEX NAME)




L6 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1986:600516 CAPLUS
 DOCUMENT NUMBER: 105:200516
 ORIGINAL REFERENCE NO.: 105:32195a, 32198a
 TITLE: Fine insulator pattern formation
 INVENTOR(S): Kataoka, Fumio; Shoji, Fusaji
 PATENT ASSIGNEE(S): Hitachi, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61067228	A	19860407	JP 1984-187916	19840910
PRIORITY APPLN. INFO.:			JP 1984-187916	19840910

GI



AB The claimed patterning process involves the following steps: (1) formation of a polyimide insulator layer on a substrate; (2) coating of the insulator layer with a Si-containing polyimide precursor type photosensitive (or radiation-sensitive) layer; (3) drying of the photosensitive layer at 50-120°; (4) patternwise exposure of the photosensitive layer; (5) development; (6) hardening of the pattern at 150-500° to form a polyimide pattern; and (7) O plasma treatment to improve the plasma etching resistance of the polyimide pattern and to etch the polyimide insulator layer to give a 2-layer structured insulator pattern. Thus, a Si substrate was coated with P/Q (a polyimide), then coated with a polyimide precursor having repeating units of the formula I, dried at 70°, imagewise exposed to deep UV, developed, heated at 350°, and etched in an O plasma to give a fine polyimide pattern.

IT 105062-28-0


RL: USES (Uses)

(resist composition containing, for polyimide insulator pattern formation)

RN 105062-28-0 CAPLUS

CN Poly[oxy(dimethylsilylene)-1,3-propanediyliminocarbonyl[4,4'-bis[[[2-[(2-methyl-1-oxo-2-propenyl)oxy]ethyl]amino]carbonyl][1,1'-biphenyl]-3,3'-diyl]carbonylimino-1,3-propanediyl(dimethylsilylene)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

]

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

126.31

307.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-18.40

-18.40

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:42:34 ON 27 AUG 2008